Back to news

Pivotal acquires Akcelis, an industry leader in patient engagement, recruitment and retention

New patients´ enrollment model to accelerate drug development

 

Pivotal announced today the acquisition of Akcelis BVBA, a leading full-service provider of patients´ enrollment and retention solutions for clinical trials in the life sciences´ industry.

“This acquisition fits perfectly well with our commitment to bringing innovation to the clinical development process to deliver efficiencies for our clients,” Lidia Farr, VP Corporate Development and Finance at Pivotal, said. “Akcelis will bring advanced, proprietary and analytics-driven technology and services to customize the most efficient and cost-effective approach to significantly improve sites´ selection and patients´ enrollment and retention strategy for our clients´ clinical trials. As we focus on delivering this value for our customers, we are pleased to welcome our new colleagues to Pivotal to be part of our solution-oriented culture and help advance drug development to improve patients’ lives.”

The acquisition promises to fundamentally redefine the entire patient´s recruitment lifecycle. United by a common culture, Akcelis brings to Pivotal the right experience to recruit and retain unique patients´ population in hard-to-recruit trials. Patients´ recruitment is a well-known bottleneck in clinical trials as many Sponsors experience challenges within this across many therapeutic areas.

Providing analytics-driven services to many large and mid-sized pharmaceutical companies, Akcelis manages the entire patients´ recruitment lifecycle, from recruitment to enrollment to retention. These services utilize innovative, proprietary and highly predictive software´s analytics to customize the most efficient and cost-effective approach to recruiting patients for a customer’s clinical trial.

“Pivotal’s expertise in clinical research and Akcelis’ patient-centric approach to accelerate patient recruitment are the winning combination for scientifically elegant and patient-friendly clinical trials,” said Barbara D’haene and Nathalie Niclaus, Akcelis Managing Directors and Founders. “We look forward to positively impacting Pivotal’s clinical research excellence by implementing innovative digital patient recruitment strategies.”

Akcelis´ integration will allow Pivotal to increase its services offering and provide its current and future clients with patients´ recruitment experts who can contribute with their expertise, advice and solid track record to provide quality accelerated patients´ recruitment strategies across prospective clinical trials.

 

MEDIA CONTACT

Ms. Natalia Farr

natalia.farr@pivotalcr.com